The approval of BTK and PI3K inhibitors (ibrutinib, idelalisib) represents a revolution in the
therapy of B cell malignancies such as chronic lymphocytic leukemia (CLL), mantle-cell …

Abstract Phosphoinositide-specific phospholipase Cs (PLCs) are expressed in all
mammalian cells and play critical roles in signal transduction. To obtain a comprehensive …

The covalent Bruton's tyrosine kinase inhibitors (BTKis) are highly effective for the treatment
of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with …

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib provides effective treatment for patients
with chronic lymphocytic leukemia (CLL), despite extensive heterogeneity in this disease. To …

Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist,
venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL) …

Abstract Purpose: Mutations in BTK, PLCG2, and BCL2 have been reported in patients with
progressive disease (PD) on continuous single-agent BTK or BCL2 inhibitor treatment. We …

Bruton tyrosine kinase (BTK) is an important signaling hub that activates the B-cell receptor
(BCR) signaling cascade. BCR activation can contribute to the growth and survival of B-cell …

Since the first clinical report in 2013, inhibitors of the intracellular kinase BTK (BTKi) have
profoundly altered the treatment paradigm of B cell malignancies, replacing chemotherapy …

Ibrutinib is the first Bruton's tyrosine kinase (BTK) inhibitor, which showed significant clinical
activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) …

Phosphatidylinositol-specific phospholipase Cγ2 (PLCγ2) is a critical signaling molecule
activated downstream from a variety of cell surface receptors that contain an intracellular …